Vaxxas announced that it received a $3.67 million award to conduct studies of a typhoid vaccine delivered by its needle-free device. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to the […]
Funding Roundup
Advanced NanoTherapies picks up $4M investment for drug-coated balloon development
Advanced NanoTherapies announced today that it collected a $4 million Series A extension from an undisclosed strategic investor. Los Gatos, California-based Advanced NanoTherapies received the investment from a medical device company. It also announced the successful treatment of the first cohort of study participants in its drug-coated balloon trial. The first-in-human trial evaluates initial short-term […]
Nemaura Medical secures $6.5M in funding
Nemaura Medical (Nasdaq:NMRD) announced that it brought in $6.5 million in non-dilutive funding through a clean debt facility. The Loughborough, England-based company said its debt facility features no warrants or convertible elements. It comes from the company’s existing lender. Nemaura Medical did not list an intended use for the added funds. The company develops daily, […]
Kindeva wins £33M grant from UK to enhance drug-delivering inhalers
Kindeva Drug Delivery announced that it received a grant from a UK fund worth a $42.2 million (£33 million) investment. The grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) aims to help Kindeva enhance inhaler manufacturing and sustainability. Funds improve Kindeva’s capability and capacity to manufacture the next generation of green pressurized […]
UroGen to raise $120M to support sustained release hydrogel delivery platform
UroGen Pharma (Nasdaq:URGN) announced that it entered into a securities purchase agreement worth approximately $120 million. The placement includes the issuance of nearly 12.6 million ordinary shares or pre-funded warrants priced at $9.54 per share. UroGen expects the placement to close on or about today, subject to customary closing conditions. RA Capital Management and Great […]
DiogenX raises $30M for regenerative diabetes treatment
DiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells. Marseille, France-based DiogenX aims to use the funds to advance its lead drug candidate into clinical development. The company designed the disease-modifying, recombinant protein to treat patients with type 1 diabetes. It modulates the Wnt/β-catenin signalling […]
Micron Biomedical raises $17M for needle-free drug delivery tech
Micron Biomedical announced today that it added $3 million to its Series A, bringing the total funding to $17 million. Atlanta-based Micron develops dissolvable, microarray-based products to simplify the delivery of drugs and vaccines. J2 Ventures provided the additional $3 million. J2 Ventures Partner Dr. Matt Goldman joins Micron’s board as an observer following the […]
Dexcom proposes $1B offering of convertible senior notes
Dexcom (Nasdaq:DXCM) today announced that it intends to offer $1 billion in convertible senior notes due in 2028. The continuous glucose monitor (CGM) maker made its private placement to persons reasonably considered qualified institutional buyers. San Diego-based Dexcom also plans to grant the initial purchasers of the notes an option to buy more. Those options […]
The biggest medical device VC deals of 2022
Last year was definitely a slower year for medical device VC deals than the year before. Biofourmis was the only medical device developer in the 10 largest healthcare VC deals of 2022, according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB). Because we love devices at Medical Design & Outsourcing, we asked SVB for a […]
EOFlow invests $7.7B in Pharmeo subsidiary for non-insulin drug delivery development
EOFlow announced today that it plans to invest $7.7 billion (9.9 billion Korean Won) in its wholly-owned Pharmeo subsidiary. The investment aims to advance R&D and commercialization of non-insulin drugs with EOFlow’s wearable drug delivery system. EOFlow intends to finance this investment through paid-in capital increase for the subsidiary. EOFlow owes the actual investment, totaling […]